Boehringer Ingelheim announces finalists of the Making More Health Accelerator Program

Boehringer IngelheimBoehringer Ingelheim, one of the world's leading pharmaceutical companies, recently announced to support two projects of its Making More Health Accelerator Program: Melissa Menke, CEO of Access Ayfa and Joost van Engen, CEO of Healthy Entrepreneurs.

Four social ventures participated in the 2018 - 2019 accelerator program, where they developed innovative business models to solve unmet medical needs in sub Saharan Africa. Boehringer Ingelheim will continue to support the scale up of two of these models through funding of €150,000 per social venture. By using this unique approach, Boehringer Ingelheim is creating a win for communities by developing innovative and sustainable care delivery models, thus improving access to healthcare.

Melissa Menke pitched for a comprehensive diabetes and hypertension screening and clinical management program within low-income populations. Her organization, Access Afya, is a primary healthcare enterprise providing quality healthcare to low income groups in slums in Nairobi, Melissa aims to have 50 clinics across Kenya by 2021. Joost Van Engen, the founder of Healthy Entrepreneurs, pitched on a last mile distribution model for medicines and other basic commodities in rural western Kenya through a network of community entrepreneurs. With this concept, Healthy Entrepreneurs will be able to offer screening services, disease awareness and provide, through a combination of telemedicine and in-person doctor visits, accessible and affordable healthcare services.

"The patients will be the most important part of this program. Many people do not have the right access to quality treatment in Africa. By supporting the social entrepreneurs, patients will be provided with better access to healthcare." Ayman Eissa, Head of Human Pharma, Boehringer Ingelheim META.

The Making More Health (MMH) Accelerator is an 11-month business accelerator program, designed through a collaboration between Boehringer Ingelheim and Ashoka. Boehringer's business insights combined with Ashoka's extensive knowledge on social entrepreneurship gives a perfect foundation to provide a structured process to engage with social entrepreneurs and co-create successful business models.

Boehringer Ingelheim's initiative "Making More Health" aims to establish a network of social enterprises in Kenya, Nigeria and Ghana by building an ecosystem ‘on the ground’ which will help in developing holistic models that will sustainably provide quality healthcare to underserved communities.

About Boehringer Ingelheim

Improving the health of humans and animals is the goal of the research-driven pharmaceutical company Boehringer Ingelheim. The focus in doing so is on diseases for which no satisfactory treatment option exists to date. The company therefore concentrates on developing innovative therapies that can extend patients’ lives. In animal health, Boehringer Ingelheim stands for advanced prevention.

Family-owned since it was established in 1885, Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies. Some 50,000 employees create value through innovation daily for the three business areas human pharmaceuticals, animal health and biopharmaceuticals. In 2018, Boehringer Ingelheim achieved net sales of around 17.5 billion euros. R&D expenditure of almost 3.2 billion euros, corresponded to 18.1 per cent of net sales.

As a family-owned company, Boehringer Ingelheim plans in generations and focuses on long-term success. The company therefore aims at organic growth from its own resources with simultaneous openness to partnerships and strategic alliances in research. In everything it does, Boehringer Ingelheim naturally adopts responsibility towards mankind and the environment.

Most Popular Now

Pfizer and Lilly announce top-line results from lo…

Pfizer Inc. (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) announced top-line results from a Phase 3 study evaluating tanezumab 2.5 mg and 5 mg. The objective of the stu...

Bristol-Myers Squibb reports first quarter financi…

Bristol-Myers Squibb Company (NYSE:BMY) today reported results for the first quarter of 2019 which were highlighted by strong demand for Opdivo (nivolumab) and Eliquis (a...

Walnuts may help lower blood pressure for those at…

When combined with a diet low in saturated fats, eating walnuts may help lower blood pressure in people at risk for cardiovascular disease, according to a new Penn State ...

Amgen ignites a social fitness movement to support…

Amgen (NASDAQ:AMGN) launched the Breakaway Challenge initiative, a national social fitness program to motivate individuals to take action in their health and to support t...

Comprehensive tumor profiling promises new therape…

The WINTHER trial, NCT01856296, led by investigators from Vall d'Hebron Institute of Oncology - VHIO (Spain), Chaim Sheba Medical Center (Israel) (Raanan Berger), Gustave...

AstraZeneca starts artificial intelligence collabo…

AstraZeneca and BenevolentAI today began a long-term collaboration to use artificial intelligence (AI) and machine learning for the discovery and development of new treat...

Possible link between autism and antidepressants u…

An international team led by Duke-NUS Medical School has found a potential link between autistic-like behaviour in adult mice and exposure to a common antidepressant in t...

Chemotherapy or not?

Case Western Reserve University researchers and partners, including a collaborator at Cleveland Clinic, are pushing the boundaries of how "smart" diagnostic-imaging machi...

Researchers define Alzheimer's-like brain disorder

A brain disorder that mimics symptoms of Alzheimer's disease has been defined with recommended diagnostic criteria and guidelines for advancing future research on the con...

Drugs to prevent stroke and dementia show promise …

Treatments that prevent recurrence of types of stroke and dementia caused by damage to small blood vessels in the brain have moved a step closer, following a small study...

Amgen and Syapse enter precision medicine collabor…

Amgen (NASDAQ:AMGN), a world leader in biotechnology, and Syapse, a company powering precision medicine insights through its global provider network, announced a precisio...

Personalizing precision medicine with combination …

Precision oncology often relies on treating patients with a single, molecularly matched therapy that targets one mutation in their tumor. In a report, published online in...